Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community

JAMA Neurology

Volumn 73, Issue 1, 2016, Pages 85-92

  Petersen, Ronald C ^a   Wiste, Heather J ^a   Weigand, Stephen D ^a   Rocca, Walter A ^a   Roberts, Rosebud O ^a   Mielke, Michelle M ^a   Lowe, Val J ^a   Knopman, David S ^a   Pankratz, Vernon S ^b   Machulda, Mary M ^a   Geda, Yonas E ^a   Jack, Clifford R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; AMYLOID BETA PROTEIN;

AGE; AGED; ALZHEIMER DISEASE; APOE4 GENE; ARTICLE; ATTENTION; BRAIN SIZE; COGNITION; CONTROLLED STUDY; DEPTH PERCEPTION; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; LANGUAGE; LONGITUDINAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BRAIN; COGNITIVE DEFECT; COHORT ANALYSIS; DEMOGRAPHY; DIAGNOSTIC IMAGING; HEALTH SURVEY; METABOLISM; PHYSIOLOGY; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BIOMARKERS; BRAIN; COGNITION; COGNITIVE DYSFUNCTION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; POPULATION SURVEILLANCE; POSITRON-EMISSION TOMOGRAPHY; RESIDENCE CHARACTERISTICS;

EID: 84954271511     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.3098     Document Type: Article

References (34)

1. Mormino EC, Kluth JT, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated ß-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5): 1310-1323.
2. Jack CR Jr, Lowe VJ,Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal,mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(pt 5): 1355-1365.
3. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461(7266): 916-922.
4. Jack CR Jr, Knopman DS, JagustWJ, et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2): 207-216.
5. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 2013;80(6): 1347-1358.
6. Jack CR Jr,Wiste HJ,Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20): 1732-1740.
7. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 280-292.
8. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: Stopping AD before symptoms begin? Sci Transl Med. 2014;6(228): 228fs13.
9. Chetelat G, Villemagne VL, Pike KE, et al; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group. Independent contribution of temporal ß-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain. 2011;134(pt 3): 798-807.
10. Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013; 80(14): 1341-1348.
11. Lim YY, Maruff P, Pietrzak RH, et al; AIBL Research Group. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain. 2014;137(pt 1): 221-231.
12. Chetelat G, Villemagne VL, Villain N, et al; AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high ß-amyloid deposition. Neurology. 2012;78(7): 477-484.
13. Schott JM, Bartlett JW, Fox NC, Barnes J; Alzheimer's Disease Neuroimaging Initiative Investigators. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aß1-42. Ann Neurol. 2010;68 (6): 825-834.
14. Roberts RO, Geda YE, Knopman DS, et al. TheMayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008; 30(1): 58-69.
15. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993; 43(11): 2412-2414.
16. Ivnik RJ, Malec JF, Smith GE, et al. Mayo's Older Americans Normative Studies: WAIS-R, WMS-R, and AVLT norms for ages 56 through 97. Clin Neuropsychol. 1992;6: 1-104.
17. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3): 183-194.
18. Jack CR Jr,Wiste HJ, Knopman DS, et al. Rates of ß-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology. 2014; 82(18): 1605-1612.
19. Freeborough PA, Fox NC. The boundary shift integral: An accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging. 1997;16(5): 623-629.
20. Jack CR Jr,Wiste HJ, Vemuri P, et al; Alzheimer's Disease Neuroimaging Initiative. Brain ß-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression frommild cognitive impairment to Alzheimer's disease. Brain. 2010;133(11): 3336-3348.
21. Landau SM, Harvey D, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7): 1207-1218.
22. AlbertMS, DeKosky ST, Dickson D, et al. The diagnosis ofmild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 270-279.
23. Doraiswamy PM, Sperling RA, Johnson K, et al; AV45-A11 Study Group. Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study. Mol Psychiatry. 2014;19(9): 1044-1051.
24. Chetelat G, La Joie R, Villain N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin. 2013;2: 356-365.
25. Villemagne VL, Burnham S, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol. 2013;12(4): 357-367.
26. Kantarci K, Lowe V, Przybelski SA, et al. APOE modifies the association between Aß load and cognition in cognitively normal older adults. Neurology. 2012;78(4): 232-240.
27. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66(12): 1476-1481.
28. Lim YY, Ellis KA, Pietrzak RH, et al; AIBL Research Group. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012;79(16): 1645-1652.
29. Pietrzak RH, Lim YY, Ames D, et al; Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group. Trajectories of memory decline in preclinical Alzheimer's disease: Results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol Aging. 2015;36(3): 1231-1238.
30. Mormino EC, Betensky RA, Hedden T, et al; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study. Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20): 1760-1767.
31. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with ß-amyloid imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing. Ann Neurol. 2013;74(6): 905-913.
32. Petersen RC, Aisen P, Boeve BF, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74(2): 199-208.
33. Jack CR Jr, Knopman DS,Weigand SD, et al. An operational approach to NIA-AA crtiteria for preclinical Alzheimer's disease. Ann Neurol. 2012;71 (6): 765-775.
34. Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013;70(12): 1512-1519.